Next-generation vaccines against gastrointestinal mucosal pathogens: kick-off meeting in Munich

Led by the Institute for medical microbiology, immunology and hygiene, Technical University of Munich (TUM), the Vax2Muc consortium’s overall aim is to improve mucosal vaccines developing novel vaccine technologies and strategies tailored for mucosal application.

The Vax2Muc consortium brings together the following partners, among universities, research organisations and SMEs: Helmholtz Centre For Infection Research (DE), Statens Serum Institut (DK), Faculdade De Farmácia Da Universidade De Lisboa (PT), Trinity College Dublin (IE), InStar Technologies a.s. (CZ), Universiteit Antwerpen (BE), IRTA Institute of Agrifood Research and Technology (ES), University of Strathclyde (UK).

In addition, LINQ management GmbH, a consulting company based in Berlin, will facilitate the administrative, financial and contractual management and support project communication, dissemination and exploitation during the course of the entire project Vax2Muc.